Opus Genetics Q2 net loss narrows to $7.4M; FDA grants RMAT for OPGx-LCA5

Opus Genetics, Inc.

2025-Q2 EPS reported -$0.32 vs consensus -$0.21 ▼ miss (-54.5%)

Net loss $7.4M ($0.12/share) vs $7.8M ($0.30) in Q2 2024; revenue $2.9M from Viatris collaboration.
FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 gene therapy.
Positive 12-month adult and early pediatric data for OPGx-LCA5; 3-month pediatric data due Q3 2025.
Phentolamine Phase 3 VEGA-3 (presbyopia) and LYNX-2 met primary endpoints; sNDA submission planned H2 2025.
Cash $32.4M expected to fund operations into H2 2026; up to $3.6M non-dilutive funding secured for RDH12 and MERTK programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.